RNA interference in the treatment of colon cancer

BioDrugs

Volumn 27, Issue 4, 2013, Pages 317-327

  Prados, Jose ^a   Melguizo, Consolacion ^a   Roldan, Hector ^b   Alvarez, Pablo J ^a   Ortiz, Raul ^c   Arias, Jose L ^a   Aranega, Antonia ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b Andalusian Public Health System Biobank   (Spain)

^c UNIVERSITY OF JAÉN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR RECEPTOR; MUCIN 2; OSTEOPONTIN; RHO FACTOR; STAT3 PROTEIN; STAT6 PROTEIN; SURVIVIN; TETRASPANIN; VASCULOTROPIN;

COLON CANCER; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE;

EID: 84880849707     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-013-0019-4     Document Type: Review

References (81)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765-81.
2. Strillacci A, Griffoni C, Lazzarini G, et al. Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells. Br J Cancer. 2010;103:975-86.
3. Yang J, Sun M, Zhang A, et al. Adenovirus-mediated siRNA targeting Bcl-xL inhibits proliferation, reduces invasion and enhances radiosensitivity of human colorectal cancer cells. World J Surg Oncol. 2011;9:117.
4. Tuschl T, Zamore PD, Lehmann R, et al. Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev. 1999;13:3191-7.
5. Wang X, Chen Y, Ren J, et al. Small interfering RNA for effective cancer therapies. Mini Rev Med Chem. 2011;11:114-24.
6. Kurreck J. Antisense technologies, improvement through novel chemical modifications. Eur J Biochem. 2003;270:1628-44.
7. Zinkel S, Gross A, Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death Differ. 2006;13:1351-9.
8. Nakamura K, Abu Lila AS, Matsunaga M, et al. A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA. Mol Ther. 2011;19:2040-7.
9. Charames GS, Bapat B. Cyclooxygenase-2 knockdown by RNA interference in colon cancer. Int J of Oncol. 2006;28:543-9.
10. Moreira L, Castells A. Cyclooxygenase as a target for colorectal cancer chemoprevention. Curr Drug Targets. 2011;12:1888-94.
11. Strillacci A, Griffoni C, Spisni E, et al. RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cells. Br J Cancer. 2006;94:1300-10.
12. Strillacci A, Griffonia C, Sansoneb P, et al. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res. 2009;315:1439-47.
13. Wu ZL, Song YQ, Shi YF, et al. High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J Hematol Oncol. 2011;4:31.
14. Zhang M, Zhou Y, Xie C, et al. STAT6 specific shRNA inhibits proliferation and induces apoptosis in colon cancer HT-29 cells. Cancer Lett. 2006;243:38-46.
15. Qian WF, Guan WX, Gao Y, et al. Inhibition of STAT3 by RNA interference suppresses angiogenesis in colorectal carcinoma. Braz J Med Biol Res. 2011;44:1222-30.
16. Lin L, Liu A, Peng Z, et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res. 2011;71:7226-37.
17. Takahashi Y, Nishioka K. Therapeutic approaches targeting tumor vasculature in gastrointestinal cancers. Front Biosci (Elite Ed). 2011;3:541-8.
18. Mulkeen AL, Silva T, Yoo PS, et al. Short interfering RNA-mediated gene silencing of vascular endothelial growth factor: effects on cellular proliferation in colon cancer cells. Arch Surg. 2006;141:367-74.
19. Yin Y, Cao LY, Wu WQ, et al. Blocking effects of siRNA on VEGF expression in human colorectal cancer cells. World J Gastroenterol. 2010;16:1086-92.
20. Li TJ, Song JN, Kang K, et al. RNA interference-mediated gene silencing of vascular endothelial growth factor in colon cancer cells. World J Gastroenterol. 2007;13:5312-6.
21. He XW, Yu X, Liu T, et al. Vector-based RNA interference against vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of colorectal cancer in vivo in mice. Chin Med J (Engl). 2008;121:439-44.
22. Liu YL, Yang YM, Xu H, et al. Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer. J Gastroenterol Hepatol. 2010;25:1800-5.
23. Kim WJ, Christensen LV, Jo S, et al. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol Ther. 2006;14:343-50.
24. Rush JS, Quaintly LM, Engelman L, et al. Endosomal accumulation of the activated epidermal growth factor receptor (EGFR) induces apoptosis. J Biol Chem. 2011;287:712-22.
25. Wu X, Deng Y, Wang G, et al. Combining siRNAs at two different sites in the EGFR to suppress its expression, induce apoptosis, and enhance 5-fluorouracil sensitivity of colon cancer cells. J Surg Res. 2007;138:56-63.
26. Rathinam R, Berrier A, Alahari SK. Role of Rho GTPases and their regulators in cancer progression. Front Biosci. 2011;16:2561-71.
27. Liu XP, Wang H, Yang K, et al. Inhibitory effects of adenovirus mediated tandem expression of RhoA and RhoC shRNAs in HCT116 cells. J Exp Clin Cancer Res. 2009;28:52.
28. Haibo W, Zhao G, Liu X, et al. Silencing of RhoA and RhoC expression by RNA interference suppresses human colorectal carcinoma growth in vivo. J Exp Clin Cancer Res. 2010;29:123.
29. Jiang L, Lai YK, Zhang J, et al. Targeting S100P inhibits colon cancer growth and metastasis by Lentivirus-mediated RNA interference and proteomic analysis. Mol Med. 2011;17:709-16.
30. Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 2007;7:847-59.
31. Kaneda H, Arao T, Tanaka K, et al. FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. Cancer Res. 2010;70:2053-63.
32. Szajda SD, Jankowska A, Zwierz K. Carbohydrate markers in colon carcinoma. Dis Markers. 2008;25:233-42.
33. Bu X, Li L, Li N, et al. Suppression of mucin 2 enhances the proliferation and invasion of LS174T human colorectal cancer cells. Cell Biol Int. 2011;35:1121-9.
34. Xiaoyuan C, Longbang C, Jinghua W, et al. Survivin: a potential prognostic marker and chemoradiotherapeutic target for colorectal cancer. Ir J Med Sci. 2010;179:327-35.
35. Pavlidou A, Dalamaga M, Kroupis C, et al. Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR. World J Gastroenterol. 2011;17:1614-21.
36. Shen W, Wang CY, Wang XH, et al. Oncolytic adenovirus mediated survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo. J Exp Clin Cancer Res. 2009;28:81.
37. Chu X, Chen L, Wang J, et al. SiRNA-mediated survivin inhibition enhances chemo- or radiosensitivity of colorectal cancer cells in tumor-bearing nude mice. Hepatogastroenterology. 2010;57:1445-52.
38. Chu XY, Chen LB, Wang JH, et al. Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. J Surg Oncol. 2012;105:520-8.
39. Wang X, Fu Z, Zhao Y, et al. Profile of protein expression of the colon cancer cell line SW480 with survivin/shRNA. Eur J Cancer Prev. 2011;20:190-8.
40. Arjomandi M, Frelinger J, Donde A, et al. Secreted osteopontin is highly polymerized in human airways and fragmented in asthmatic airway secretions. PLoS One. 2011;6:e25678.
41. Wai PY, Mi Z, Guo H, et al. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis. 2005;26:741-51.
42. Likui W, Hong W, Shuwen Z, et al. The potential of osteopontin as a therapeutic target for human colorectal cancer. J Gastrointest Surg. 2011;15:652-9.
43. Rubie C, Frick VO, Ghadjar P, et al. CXC receptor-4 mRNA silencing abrogates CXCL12-induced migration of colorectal cancer cells. J Transl Med. 2011;9:22.
44. Abedini F, Ismail M, Hosseinkhani H, et al. Effects of CXCR4 siRNA/dextran-spermine nanoparticles on CXCR4 expression and serum LDH levels in a mouse model of colorectal cancer metastasis to the liver. Cancer Manag Res. 2011;3:301-9.
45. Chang LY, Lin YC, Mahalingam J, et al. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res. 2012;72:1092-102.
46. Chen L, Yuan D, Zhao R, et al. Suppression of TSPAN1 by RNA interference inhibits proliferation and invasion of colon cancer cells in vitro. Tumori. 2010;96:744-50.
47. Lin F, Wang R, Shen JJ, et al. Knockdown of RCK/p54 expression by RNAi inhibits proliferation of human colorectal cancer cells in vitro and in vivo. Cancer Biol Ther. 2008;7:1669-76.
48. Butcher NJ, Minchin RF. Arylamine N-acetyltransferase 1: a novel drug target in cancer development. Pharmacol Rev. 2012;64:147-65.
49. Fan Y, Zong WX. Hacking hexokinase halts tumor growth. Cancer Biol Ther. 2008;7:1136-8.
50. Tiang JM, Butcher NJ, Cullinane C, et al. RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition. PLoS One. 2011;6:e17031.
51. Chen Z, Zhang H, Lu W, et al. Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate. Biochim Biophys Acta. 2009;1787:553-60.
52. Neary CL, Pastorino JG. Nucleocytoplasmic shuttling of hexokinase II in a cancer cell. Biochem Biophys Res Commun. 2010;394:1075-81.
53. Peng Q, Zhou Q, Zhou J. Stable RNA interference of hexokinase II gene inhibits human colon cancer LoVo cell growth in vitro and in vivo. Cancer Biol Ther. 2008;7:1128-35.
54. Peng Q, Zhou J, Zhou Q, et al. Silencing hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Hepatogastroenterology. 2009;56:355-60.
55. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA. 2003;100:11606-11.
56. Berezovska OP, Glinskii AB, Yang Z, et al. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle. 2006;5:1886-901.
57. Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007;21:1050-63.
58. Holland D, Hoppe-Seyler K, Schuller B, et al. Activation of the enhancer of Zeste homologue 2 gene by the human papillomavirus E7 oncoprotein. Cancer Res. 2008;68:9964-72.
59. Fussbroich B, Wagener N, Macher-Goeppinger S, et al. EZH2 depletion blocks the proliferation of colon cancer cells. PLoS One. 2011;6:e21651.
60. Sureban SM, May R, George RJ, et al. Knockdown of RNA binding protein musashi-1 leads to tumor regression in vivo. Gastroenterology. 2008;134:1448-58.
61. Yokota N, Mainprize TG, Taylor MD, et al. Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization. Oncogene. 2004;23:3444-53.
62. Kanemura Y, Mori K, Sakakibara S, et al. Musashi1, an evolutionarily conserved neural RNA-binding protein, is a versatile marker of human glioma cells in determining their cellular origin, malignancy, and proliferative activity. Differentiation. 2001;68:141-52.
63. Ma YH, Mentlein R, Knerlich F, et al. Expression of stem cell markers in human astrocytomas of different WHO grades. J Neurooncol. 2008;86:31-45.
64. Schulenburg A, Cech P, Herbacek I, et al. CD44-positive colorectal adenoma cells express the potential stem cell markers musashi antigen (msi1) and ephrin B2 receptor (EphB2). J Pathol. 2007;213:152-60.
65. Li D, Peng X, Yan D, et al. Msi-1 is a predictor of survival and a novel therapeutic target in colon cancer. Ann Surg Oncol. 2011;18:2074-83.
66. Hegedus Z, Czibula A, Kiss-Toth E. Tribbles: novel regulators of cell function; evolutionary aspects. Cell Mol Life Sci. 2006;63:1632-41.
67. Miyoshi N, Ishii H, Mimori K, et al. Abnormal expression of TRIB3 in colorectal cancer: a novel marker for prognosis. Br J Cancer. 2009;101:1664-70.
68. Brown CJ, Dastidar SG, Quah ST, et al. C-terminal substitution of MDM2 interacting peptides modulates binding affinity by distinctive mechanisms. PLoS One. 2011;6:e24122.
69. Yu Y, Sun P, Sun LC, et al. Downregulation of MDM2 expression by RNAi inhibits LoVo human colorectal adenocarcinoma cells growth and the treatment of LoVo cells with mdm2siRNA3 enhances the sensitivity to cisplatin. Biochem Biophys Res Commun. 2006;339:71-8.
70. Walker A, Acquaviva C, Matsusaka T, et al. UbcH10 has a rate-limiting role in G1 phase but might not act in the spindle checkpoint or as part of an autonomous oscillator. J Cell Sci. 2008;121:2319-26.
71. Chen SM, Jiang CY, Wu JY, et al. RNA interference-mediated silencing of UBCH10 gene inhibits colorectal cancer cell growth in vitro and in vivo. Clin Exp Pharmacol Physiol. 2010;37:525-9.
72. Atanassov BS, Dent SY. USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1. EMBO Rep. 2011;12:924-30.
73. Liu Y, Yang Y, Xu H, et al. Implication of USP22 in the regulation of BMI-1, c-Myc, p16INK4a, p14ARF, and cyclin D2 expression in primary colorectal carcinomas. Diagn Mol Pathol. 2010;19:194-200.
74. Xu H, Liu YL, Yang YM, et al. Knock-down of ubiquitin-specific protease 22 by micro-RNA interference inhibits colorectal cancer growth. Int J Colorectal Dis. 2012;27:21-30.
75. Chen SH, Zhaori G. Potential clinical applications of siRNA technique: benefits and limitations. Eur J Clin Invest. 2011;41:221-32.
76. Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011;12:329-40.
77. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 2005;23:338-51.
78. Tanaka T, Kuroki M, Hamada H, et al. Cancer-targeting gene therapy using tropism-modified adenovirus. Anticancer Res. 2007;27:3679-84.
79. Keates AC, Fruehauf JH, Xiang SO, et al. Cequent Pharmaceuticals, Inc.: the biological pitcher for RNAi therapeutics. Pharmacogenomics. 2007;8:867-71.
80. Miele E, Spinelli GP, Miele E, et al. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine. 2012;7:3637-57.
81. Shahzad MM, Mangala LS, Han HD, et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia. 2011;13:309-19.